International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma

BACKGROUND: The International Prognostic Index (IPI) is widely used to discriminate the prognosis of patients with diffuse large B-cell lymphoma (DLBCL). However, there is a significant need to identify novel valuable biomarkers in the context of targeted therapy, such as immune checkpoint blockade...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Shidai, Shi, Deyao, Ai, Lisha, Fan, Fengjuan, Peng, Fei, Sun, Chunyan, Hu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569825/
https://www.ncbi.nlm.nih.gov/pubmed/34745101
http://dx.doi.org/10.3389/fimmu.2021.732006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569825/
https://www.ncbi.nlm.nih.gov/pubmed/34745101
http://dx.doi.org/10.3389/fimmu.2021.732006

Ejemplares similares